Actively Recruiting
Evaluating Continuation of Systemic Therapy After Local Ablative Treatment for Limited Progression in Metastatic Breast Cancer
Led by The Netherlands Cancer Institute · Updated on 2026-09-11
56
Participants Needed
7
Research Sites
261 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the continuation of the same systemic therapy after applying local ablative therapy LAT for patients with metastatic breast cancer that shows oligoprogression during palliative treatment. Oligoprogression is defined as limited progression in one or two lesions and this study focuses on patients with invasive breast cancer who have metastatic disease and are receiving systemic therapy. The study is a phase 2 interventional trial sponsored by The Netherlands Cancer Institute. Participants will receive local ablative therapy targeted at the progressing lesions, which may include surgery, stereotactic ablative radiotherapy SABR, or percutaneous radiofrequent ablation. The choice of LAT depends on the lesions location and will follow standard care decided by the treating team. The systemic therapy, which can be endocrine, targeted, chemotherapy, or immune-checkpoint blockade, will continue unchanged during the study. Throughout the study, patients will be monitored with imaging to confirm oligoprogression and assess lesion response. Outcome measures include the number of patients free of disease progression at 6 months, overall survival, time to next treatment, and complications from LAT. The study involves ongoing follow-up for up to 120 months to observe long-term outcomes. Participants will undergo radiological imaging, including FDG-PET-CT scans, and clinical assessments to track treatment effects and safety.
CONDITIONS
Brief Title
COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study
Research Team
G
G Sonke, MD
R
Robin van den Borg, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here